Samsrita Labs Ltd. engages in the provision of healthcare services. The company is headquartered in Hyderabad, Telangana and currently employs 4 full-time employees. The company went IPO on 2015-08-10. The firm is engaged in activities, such as trading, exports and imports, manufacturing of bulk drugs, research, and development (R&D) through joint ventures or associations or mergers or by its own. The company has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology, and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nanoformulation of cancer drugs, molecular genetics and molecular virology, stem cell, and cord blood banking. Its Molecular Prognosis and Diagnostics services division provides molecular diagnostics and services in the areas of cytogenetics, pharmacogenomics, pathology, radiology, hematology, biochemistry, and microbiology.